Andrew Huberman: Professor of neurobiology and ophthalmology at Stanford School of Medicine and host of the Huberman Lab Podcast, covering science-based tools for mental and physical health.
What this episode covers
In this solo episode, Andrew Huberman explains the biology of cannabis, distinguishing sativa, indica, and hybrid strains as well as type 1, type 2, and type 3 strains defined by their THC-to-CBD ratios. He details how THC and CBD bind endogenous cannabinoid (CB1 and CB2) receptors far more potently than the body's own anandamide and 2-AG, outcompeting natural signaling and explaining effects on mood, focus, memory, appetite, and pain. He reviews the evidence on cannabis and creativity, speech changes, sexual arousal, and hormones like prolactin, testosterone, and estrogen. The episode closes with a strong warning about the documented harms of cannabis for pregnant mothers, fetuses, and anyone under age 25, including increased anxiety, depression, and risk of psychosis.
Also referenced (named, not recommended)
Virtusan
Virtusan
“This is a YouTube channel that's hosted by Virtusan, which has a terrific app that includes NSDR and a number of other health and wellness protocols”— Andrew Huberman
Dianabol
Ciba
“in the body building community and the sports community, they will take things like Dianabol. These are modified versions of testosterone that can bind to the testosterone receptor with much greater affinity”— Andrew Huberman
Big reveals from this episode
- THC and CBD bind cannabinoid receptors with roughly thousand-fold greater potency than your own endogenous cannabinoids, leaving the natural system essentially dysfunctional.
- Cites a study concluding the cannabis-creativity link is 'largely a spurious correlation' driven by personality (openness to experience), not direct neural effects.
- Whether cannabis boosts or suppresses sexual arousal depends on whether your prolactin rises under intoxication, not your baseline prolactin.
- Calls it 'absolutely terrifying' that 15% of pregnant U.S. mothers report using cannabis, given CB1 receptors are central to fetal brain development.
- Adolescent cannabis use accelerates thinning of prefrontal cortex gray matter, dose-dependently, per a Translational Psychiatry consortium paper.
- Heavy cannabis use (more than twice per week) is associated with four times the risk of later psychosis, especially schizophrenia and bipolar-like episodes.
- Cannabis use makes people four times likelier to develop chronic major depression, even those not depressed at the outset.
Worth remembering
- The cannabis plant contains over 70 psychoactive compounds and over 400 biologically active compounds, most still unstudied in isolation.
- The three most commonly used drugs are alcohol, then nicotine (1-2 billion users), then cannabis; caffeine would top them all if counted.
- Smoked or ingested cannabis reaches the brain within 30 seconds and peaks at 30-60 minutes, lasting three to four hours.
- Because THC and CBD are highly lipophilic, they lodge in fatty tissue and can be detected for at least 80 days after use.
- Indica suppresses prefrontal cortex activity ('turn off thinking'), while the 'munchies' come from CB1 receptors densely packed in the hypothalamus.
- Speech is movement; chronic cannabis use alters 'spectral tilt' (vocal effort) and verbal timing, even when users are not intoxicated.
- Smoking cannabis clearly raises prolactin, especially with use more than twice a week, which suppresses dopamine and testosterone.
- Chronic cannabis use can raise aromatase, converting testosterone to estrogen, possibly contributing to gynecomastia in some men.
- Endogenous cannabinoids are present at much higher levels in the developing fetus than after birth, declining across development.
- The typical age of starting cannabis is about 18.7 years, and roughly 20% of 16-to-24-year-olds use it daily.